Synthetic Retatrutide Peptide Powder Laboratory Research Raw Material
197 Inquiries
2134602-45-0
Pharmaceutical Grade
99%
Shenzhen
XiWu
5mg*10Vials
2026-09-20
GLP-1,Retatrutide,Selank,Tirzepatide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
SR17018
Other Name:SR17018;CS-2685;SR1 7018;SR-17018;SR17018;2H-Benzimidazol-2-one, 5,6-dichloro-1-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1,3-dihydro-;SR 17018,SR17018,Opioid Receptor,inhibit,SR-17018,Inhibitor;SR-17018 SR17018;5,6-dichloro-1-{1-[(4-chlorophenyl)methyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one;SR17018, 10 mM in DMSO
CAS No.:2134602-45-0
Molecular Formula:C19H18Cl3N3O
InChIKeys:LAGUDYUGRSQDKS-UHFFFAOYSA-N
Molecular Weight:410.72
Exact Mass:409.051545
EC Number:218-362-5
Color/Form:White to off-white
Categories:
Characteristics-
Density:
1.428±0.06 g/cm3(Predicted)
PKA:10.03±0.30(Predicted)
Critical Temperature & Pressure:Store at -20°C
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
GLP-1,Retatrutide,Selank,Tirzepatide
-
Location:
Room 307, No. 3, Building 7, Area 4, Pingchou, Jiangdong Street, Yiwu City, Jinhua City, Zhejiang Province
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
-
Inquiry History197 Inquiries
Country Product Purchase Quantity Date Posted
Italy
SR17018 CAS 2134602-45-0
100 G Jan 12, 2026
United States
Purity 98% SR17018 2134602-45-0
1 KG Dec 23, 2025
Israel
SR-17018
5 KG Apr 12, 2026
United States
Sr17018
100 G Mar 7, 2026
Canada
SR-17018
30 G Apr 6, 2026
United States
SR-17018
50 G Jul 21, 2026
United States
SR17018
10 G Jun 4, 2026
United States
Factory direct Supply 98% Purity SR-17018 Raw Powder SR17018
5 G Mar 15, 2026
Netherlands
sr17018
20 G Aug 30, 2026
United States
SR-17018
20 MG Aug 26, 2026
United States
sr-17018
28 G Aug 20, 2026
United Kingdom
SR-17018
10 MG Aug 19, 2026
United States
sr17018
50 MG Jul 20, 2026
Netherlands
SR 17018
1 G Jul 19, 2026
United States
Sr-17018
10 G Jul 17, 2026
United States
Sr17018
20 G Jul 5, 2026
United States
High Quality 99% SR 17018
100 G Jul 2, 2026
The Dominican Republic
Sr17018
1 KG Jun 16, 2026
United States
DR-17018
1 KG Apr 22, 2026
United States
SR-17018
100 G Apr 21, 2026 Post an enquiry for this product